VRTX Vertex Pharmaceuticals Incorporated
$520.66
Vertex Pharmaceuticals Incorporated (VRTX) Earnings News
Earnings press releases, previews and reviews for Vertex Pharmaceuticals Incorporated (VRTX), newest first. Our most recent is review: Vertex Misses on EPS as Crinetics and Launch Spending Outpace a Revenue Beat, With CF Growth Cooling Ahead of Povetacicept Decision.
Monday
November 2, 2026
7:38 PM ET
Vertex Misses on EPS as Crinetics and Launch Spending Outpace a Revenue Beat, With CF Growth Cooling Ahead of Povetacicept Decision
Earnings Whispers · Review
Monday
November 2, 2026
4:01 PM ET
Vertex Reports Third Quarter 2026 Financial Results
Monday
October 26, 2026
3:14 PM ET
Vertex Heads Into Q3 With Raised Guidance as Casgevi and Gernavix Ramps Face Proof Test
Earnings Whispers · Preview
Wednesday
October 7, 2026
4:00 PM ET
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
Tuesday
September 1, 2026
9:03 AM ET
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Monday
August 3, 2026
4:01 PM ET
Vertex Reports Second Quarter 2026 Financial Results
Thursday
May 28, 2026
9:15 AM ET
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum